// App-Quantinova.ai

: Treatment- Free Remission in Chronic Myeloid Leukemia -Experience of a Single Brazilian Private Institution Using Imatinib Copies

Researchers

Presenter

  • Renato Torrescasana Centrone

Principal Investigators

  • Marcelo Bellesso

  • Rodrigo Santucci Silva

  • Daniela Ferreira Dias

  • Israel Bendit

  • Jhony ARANHA Lima Alves

  • Felipe Ribeiro Bruniera

  • Ariel Testasicca Trunkel

  • Adelson Alves da Silva

Medical Centers

  • Instituto Hemomed de Oncologia e Hematologia, São Paulo, Brazil

  • Instituto de Ensino e Pesquisa Sao Lucas - IEP Hemomed, Sao Paulo, SP, Brazil

  • Instituto Hemomed, Sao Paulo, Brazil

  • Hematology, Hemotherapy & Cell Therapy, Universidade de São Paulo (USP), Sao Paulo, Brazil

Locations

  • Brazil

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved